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Background: In 2014, six of the top ten blockbuster medicines were monoclonal
antibodies. This multibillion-dollar market with expiring patents is the main driver for
the development of biosimilar mAbs. With the ever-increasing cost of healthcare and
the economic pressure to reduce or sustain healthcare expenses, biosimilars could be
instrumental in reducing costs for medication and increasing patient access to treatment.
Objectives: The aim of this study is to identify and describe the barriers to market
access of biosimilar mAbs in the European Union and to analyze how these barriers
could be overcome.
Methods: A narrative literature review was carried out using the databases PubMed,
Embase, and EconLit. Studies were published in English or Dutch. Additionally, the
reference list of the articles was checked for relevant studies. Articles and conference
papers known to the authors were included as well. Articles were also identified by
searching on the website of the Generics and Biosimilars Initiative (GaBI) journal.
Results: Six barriers were identified based on available literature: The manufacturing
process, the regulatory process, intellectual property rights, lack of incentive, the
impossibility of substitution, and the innovator’s reach. These six barriers are
presented as a possible framework to study the market access of biosimilar mAbs.
Based on the literature search, recommendations can be made to overcome these
barriers: (i) invest initially in advanced production processes with the help of single-
use technology, experience or outsourcing (ii) gain experience with the regulatory
process and establish alignment between stakeholders (iii) limit patent litigation,
eliminate evergreening benefits, build out further the unitary patent and unified
patent litigation system within the EU (iv) create demand-side policies, disseminate
objective information (v) change attitude toward biosimilar switching/substitution,
starting with physician, and patient education (vi) differentiate the biosimilar by
service offerings, use an appropriate comparator in cost-effectiveness analyses.
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Conclusions: Barriers to the market access of biosimilar mAbs could be reduced when
more transparency and communication/education is used in all steps toward market
access in order to increase the trust in biosimilar mAbs by all stakeholders. Only then
biosimilar mAbs will be able to fully capture their cost saving potential.
Keywords: biosimilar, monoclonal antibody, market access, European Union, literature review
INTRODUCTION
Biotechnology has been widely adopted by large pharmaceutical
companies in the development of new medicines. Medicines
produced using biotechnology, biological medicines or biologics,
represent a growing share of all medicines worldwide. In 2012,
they accounted for 18% of the global market. In 2007, this was
15%, and in 2002 this was only 11% (Rickwood et al., 2013).
Monoclonal antibodies (mAbs) are a great contributor to this
growth. Today they represent a multibillion-dollar industry of
medicines used mainly in treatment of autoimmune diseases and
cancer. In 2014, eight of the top ten blockbuster medicines in
Europe were biological medicines, six of these weremAbs (Dolan,
2015). Due to the complex and costly manufacturing process and
often unique therapeutic value, biological medicines are more
expensive than small molecule chemical medicines. The high
prices and the success of biological medicines put pressure on
healthcare expenses, and this cost pressure may lead to a decrease
in patient access to medicines (McCamish and Woollett, 2012;
Rickwood and Di Biase, 2013).
Following expiry of patent and other exclusivity rights,
the market may open to non-innovator versions of biological
medicines, so-called biosimilar medicines or biosimilars, which
tend to be less expensive due to a lower research and development
(R&D) cost and possible impact of competition. In the European
Union, the European Medicines Agency (EMA) has established
a regulatory framework for registration of biosimilars since
2005. The EMA defines a biosimilar as follows: “A biosimilar
is a biological medicinal product that contains a version of the
active substance of an already authorized original biological
medicinal product (reference medicinal product) in the European
Economic Area (EEA). Similarity to the reference medicinal
product in terms of quality characteristics, biological activity,
safety and efficacy based on a comprehensive comparability
exercise needs to be established.” (EMA, 2014) Later, product
specific biosimilar guidelines were developed, e.g., for products
containing monoclonal antibodies (EMA, 2012a). In September
2013, the first biosimilar mAb for infliximab developed by
Celltrion was approved by the EMA as Inflectra R© (by Hospira)
and Remsima R© (by Celltrion). These products could not enter
the greater part of the European market until February 2015
due to prolongation of market exclusivity of the innovator
medicine Remicade R©. In 2014 global sales of the originator
product Remicade R© accounted for $9.8 billion (2014 Sales of
Recombinant Therapeutic, Antibodies and Proteins, 2015). Even
a limited price discount of 30% would create a substantial cost-
saving per treatment.
With the ever-increasing cost of healthcare and the economic
pressure to reduce or sustain healthcare expense, biosimilars
could be instrumental in reducing cost for medication and
increasing patient access to treatment (McCamish and Woollett,
2012; Rickwood andDi Biase, 2013). Especially the cost for cancer
treatment is becoming unaffordable, even for wealthy countries,
due to higher prevalence of cancer and more expensive biological
and targeted therapies (Cornes, 2012). This results in a huge
market potential for biosimilars.
The advancement in technology makes biosimilars possible
and the pressure on healthcare budgets makes them desirable.
Therefore, both a technological push and a market pull
mechanism are facilitating biosimilar mAb development. In
comparison to earlier introduced biosimilars, e.g., filgrastim
biosimilars, biosimilar mAbs are more complex in structure
and mode of action. In addition, competition from innovative
products is fierce, and the regulatory requirements for biosimilar
mAbs are more complex than for smaller biosimilars (Declerck,
2013; Mellstedt, 2013). The huge market potential nevertheless
resulted in many pharma companies investing in biosimilar mAb
development.
Although multiple patents of mAbs are expired (e.g.,
rituximab, trastuzumab; GaBI, 2015), so far only one biosimilar
mAb received marketing authorization, i.e., a biosimilar of
infliximab (European Medicines Agency, 2016a). Biosimilar
etanercept was approved early 2016 and is regarded by many
as a mAb. However, etanercept in a strict sense is not a
mAb, but a TNF receptor fusion protein. It was assessed by
EMA according to the same principles as mAbs (European
Medicines Agency, 2015a). We expect the same uptake barriers
for biosimilar etanercept. Furthermore, earlier biosimilars have
seen slow uptake in Europeanmarkets (GaBI, 2012; Farfan-Portet
et al., 2014). With the slow emergence and uptake of biosimilar
mAbs, we perceive that market access of biosimilar mAbs is
hindered by several barriers.
The aim of this study is to (a) identify the barriers to market
access of biosimilar mAbs in the European Union (EU), and (b)
analyze how these barriers could be overcome.
This manuscript is based on the MBA thesis of one of the
authors, Clara Jonker-Exler (Jonker-Exler, 2014). To the best of
the authors’ knowledge, this is the first study that (a) reviews the
literature onmarket access of a significant class of newmedicines,
i.e., biosimilar mAbs, (b) uses a framework to identify and discuss
barriers to market access of biosimilar mAbs, and (c) proposes
clear recommendations to reduce or remove such barriers.
METHODS
This study is based on a narrative literature review. Relevant
studies were identified by searching PubMed, Embase and
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EconLit up to November 2015. The following search terms
were used: “biosimilar monoclonal antibody,” “biosimilar market
entry.” Studies could be published in English or Dutch.
Additionally, the reference list of the articles was checked for
other relevant studies. Articles known to the authors were
included as well and conference papers were scrutinized for
relevant information. An additional source was the website of the
Generics and Biosimilars Initiative (GaBI) journal, GaBI Online.
Published literature was analyzed while the biosimilar mAb
market is developing faster than studies can be carried out
and published. The barriers may resolve or change over time
and there will possibly be differences between different types
of biosimilar mAbs. Even though only one biosimilar mAb is
currently on the market, patents expired for some of the highest
sold biologicals (rituximab, trastuzumab) or will expire in the
next few years (Table 1), allowing more biosimilar mAbs to enter
the market. Currently (March 2016), four dossiers for biosimilar
mAbs [infliximab (one), rituximab (one) and adalimumab (two)]
are under review at the EMA (European Medicines Agency,
2016c).
RESULTS AND DISCUSSION
Barriers to Market Access
Since literature on the market access of biosimilar mAbs is not
abundant, this paper describes the market access barriers for
biosimilars in general in case specific information on biosimilar
mAbs was not available.
With a view to undertaking a structured analysis of barriers
to biosimilar market access, this paper draws on the framework
proposed by Aaron (Ronny) Gal and the hurdles that he
identified (Gal, 2014; Gal et al., 2015). Gal’s framework was
adapted based on the available literature to develop our own
framework that allows to analyze barriers to market access
of biosimilar mAbs. Six barriers were identified based on
available literature and hurdles described by Aaron (Ronny) Gal
(Gal, 2014; Gal et al., 2015): The manufacturing process, the
TABLE 1 | Exclusivity expiration dates monoclonal antibodies in the
European Union (EU) (GaBI, 2015; European Medicines Agency, 2015c).
INN Reference Exclusivity Biosimilar Year of
product expiration EU EMA approval
Infliximab Remicade 2015 1999
Inflectra 2013
Remsima 2013
Adalimumab Humira 2018 / 2003
Etanercept* Enbrel 2015 2000
Benepali 2016
Rituximab Rituxan 2013 / 1998
Trastuzumab Herceptin 2014 / 2000
Bevacizumab Avastin 2022 / 2005
Cetuximab Erbitux 2014 / 2004
Ranibizumab Lucentis 2022 / 2007
*Not a real mAb.
regulatory process, intellectual property rights, lack of incentive,
the impossibility of substitution, and the innovator’s reach.
(Table 2) These six barriers are presented as a possible framework
to study the market access of biosimilar mAbs.
An Expensive and Complex Manufacturing Process
The barrier of scale and experience is high in the biotech pharma
industry, mainly because of high investment requirements for
manufacturing processes and learning curve effects (Simoens,
2009).
Not only the cost, but also the complexity of the
manufacturing process hinders biosimilar mAb development.
Biosimilar developing companies have no access to the
original biological expression system that was used for the
innovative reference product and therefore need to take a
reverse engineering approach (Mellstedt, 2013). Thus, full
knowledge of the production process of the innovator medicine
is not available as it is mainly protected by trade secret.
Contrary to highly predictable chemical processes, the biological
production process is more difficult to control (Lepage-Nefkens
et al., 2013), and quality attributes of the product are highly
influenced by changes in the production process, e.g., different
expression system, growth conditions,... (Declerck, 2013). This
complicates the reverse engineering of biological medicines,
and therefore the production of a highly similar biological
medicine.
Once the reverse engineering of the biosimilar mAb is
finished, and the development and testing is successful, the
company will need to upscale production and possibly open new
facilities to meet market demand. Every change in production,
including upscaling, may affect one or more quality attributes
of the product, and managing the manufacturing process will
be a continuous challenge for the biosimilar developer. Hence,
access to manufacturing technologies may be restricted to those
companies who have been investing in biologic manufacturing
platforms throughout the years (Calo-Fernández and Martínez-
Hurtado, 2012).
TABLE 2 | Barriers to market access of biosimilar monoclonal antibodies
in the European Union.
Manufacturing process • Expensive
• Complex
Regulatory process • Uneven contribution and acceptation by
stakeholders
Intellectual property rights • Innovator patents
• Prolongation of exclusivity rights
• Patent disputes
Lack of incentive • Difficult to differentiate
• Limited price discounts
• Limited knowledge and acceptance
• Burden of change
Impossibility of substitution • No interchangeability
• Little to no policies in favor of switching and
substitution
Innovator’s reach • Strong ties with physicians and patients
• Competitive rebates
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A Regulatory Process with Uneven Contribution and
Acceptation by Stakeholders
The EMA guideline for biosimilar mAbs was approved in
2012 (EMA, 2012a). Until that time, biosimilar developers were
unsure about the final regulatory requirements for biosimilar
mAbs. In 2009, EMA started with providing individual protocol
assistance and scientific consultations to companies to avoid
slowdown of the development of biosimilar mAbs (European
Medicines Agency, 2015b). Even with the published guideline,
the evaluation is very much case-by-case and the developer has
the opportunity to propose novel study techniques (Schellekens
and Moors, 2010; EMA, 2012a).
During the public consultation period of the EMA guideline
on biosimilar mAbs, industry and regulatory representatives
made comments, while the medical profession did not take
this opportunity to be involved in designing the guidelines
(Ebbers et al., 2012a). This uneven contribution to the guidelines
by different stakeholders has led to uneven commitments of
medical professionals, patients and industry to the outcome of
the guideline. This may have contributed to concerns raised
by medical professionals and patients/patient organizations,
subsequently hindering uptake of biosimilars in the market
(Aapro, 2011).
Innovator Patents, Prolongation of Exclusivity Rights,
and Patent Disputes
The earliest market entry date for a biosimilar is the latest
expiration date of relevant patents as well as data and market
exclusivity rights, but in most cases patents are the determinant
blocking market entry (Rader, 2013). Patent protection is a
legal restraint on new market entry of biosimilars, but patent
protection and market exclusivity are tools for innovator
biologicals to recover the R&D expense.
While the patent for a product, which claims the specific
amino acid sequence of the medicine, blocks market entry
of biosimilars, innovator patents on production processes and
mAb applications complicate the development of biosimilars.
Patents on manufacturing processes can be used to prevent
manufacturers of biosimilars from using the same production
processes as innovators. On the other hand, biosimilar developers
will never know the details of the production process, since
these are kept as a trade secret. Choosing or adapting different
production processes may lead to differences in the end product,
which then need to be shown as not having an effect on efficacy
and safety in patients. This adds to the burden and cost of
manufacturing process design of biosimilars and validation after
manufacturing.
The first approved biosimilar mAb, an infliximab biosimilar,
could not directly enter the greater part of the European market
due to an extension of market exclusivity of the innovator
medicine Remicade R© of 6 months, granted in return of filing an
extra indication for pediatric use (GaBI, 2013). The possibility of
prolongation of exclusivity rights, as a reward for e.g., licensing
pediatric indications, makes the date for market entry of the
biosimilar more uncertain. In addition, patents are territorial
in scope, therefore patent expiration dates may differ across
countries, which further complicates market entry.
The first company to launch a biosimilar will likely need
to resolve patent disputes and this could explain why some
companies have halted their trials (Rader, 2013; Malkin, 2015).
This leads to a complicated trade-off between postponement
of the launch date, investing high budgets in new production
processes and subsequent validation, or risking the cost and
possible loss of a patent dispute.
With the slow uptake of existing biosimilars and the
difficulties in developing biosimilar mAbs, the abrupt drop in
sales or patent cliff that innovators face is much less sharp and
acute for biologics than in the case of generic small molecules
(Calo-Fernández and Martínez-Hurtado, 2012). Nevertheless,
with the high revenues of biologics threatened by biosimilar
competition, the innovator companies are expected to fight off
and delay this competition.
Difficulties to Differentiate a Biosimilar, Low Price
Discounts, Limited Knowledge and Acceptance, and
the Burden of Change Lead to a Lack of Incentive
After marketing authorization is granted, the uptake of
biosimilars is influenced by incentives for healthcare payers,
physicians, pharmacists and patients to promote, prescribe,
dispense, and use these biosimilars.
The possible strategy of differentiation leads to the importance
of providing a biosimilar product with a greater perceived
value than the originator biological product. Where innovative
biologics are highly branded it is more difficult to differentiate
biosimilars and use this to incentivize buyers.
With the high cost of development, the biosimilar can only be
introduced on the market with a limited discount compared to
the originator. They are usually priced at a discount of only 10–
35% (Farfan-Portet et al., 2014). Absolute cost savings could still
be substantial because of the high price and high volume of the
reference medicines (Declerck and Simoens, 2012).
Physicians are hesitant to accept biosimilars as equal to the
reference product (Aapro, 2011) and they generally do not
directly benefit from the lower cost. There is a need for an
incentive to facilitate biosimilar introduction and transition
from prescribing the familiar and trusted reference product, to
prescribing a biosimilar mAb with its inherent uncertainties, and
to compensate for the effort it will take to explain to their patients
the switch to a cheaper alternative. Patients will follow the advice
of their physician and patient associations, and are influenced by
reports in general media.
Physicians aremainly concerned about patient safety and need
to choose the right treatment, based on available information
(Schellekens, 2009). The overall slow uptake of currently available
biosimilars in Europe is mainly ascribed to low physician
knowledge and acceptance of the concept of biosimilarity (Aapro,
2011; European Commission, 2013; Rickwood and Di Biase,
2013).
No Interchangeability, and Little to No Policies in
Favor of Switching and Substitution
Another barrier biosimilar mAbs face is the impossibility of
substitution in most European countries. Substitution is the
act of replacing the innovator medicine with the biosimilar, or
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one biosimilar for the other, at the pharmacy level, without the
previous consent of the prescribing physician (Boone et al., 2013).
Substitution is the reason generic medicines can gain market
share rapidly.
In Europe, the national authorities are responsible for the
legislation on substitution. So far, few countries, e.g., France and
Germany, have explicitly allowed a restricted form of biosimilar
substitution (Drozd et al., 2014; GaBI, 2014) and thereforemarket
share in Europe will need to be gained by costlymarketing or high
discounts.
The decision on interchangeability lies as well with
the national authority of the EU member states. The
evaluation by the EMA does not include a statement on
interchangeability of biosimilars on an individual level (EMA,
2012b). Interchangeability of the biosimilar is a prerequisite for
substitution. It could be argued that if a biosimilar is approved in
Europe, it is deemed interchangeable with its reference product
on a population level (Ebbers et al., 2012b). Even though this is
applicable to treatment-naïve patients, uncertainties still exist
about switching for patients during their treatment.
Switching is prescribing or dispensing a biosimilar to a patient
who was previously using the innovator medicine, or vice versa.
To enable track and trace, repeated switching and substitution
without consent of the prescribing physician are not advised
(Weise et al., 2012). A company can only live up to its post-
authorization safety study requirements if accurate track and
trace is guaranteed, so an adverse event can be traced to the exact
product causing it (Vermeer et al., 2015). It should be noted
that this is further complicated by the delay of certain adverse
events such as immunogenicity. If more biosimilars of the same
molecule enter the market, the issue is further complicated, as
a biosimilar is similar to a reference product, and similarity to
another biosimilar has not been studied.
Without the possibility of substitution, biosimilars are offered
as a choice for new patients or as a one-time switch for stable
patients only. This market segmentation makes the size of the
potential market for the biosimilar a fraction of the total market
of the reference product, especially for those products used in
long-term treatments (Rickwood and Di Biase, 2013).
Strong Ties of the Innovator Company with
Physicians and Patients, and Offering of Competitive
Non-transparent Rebates
As mentioned before, the innovator company is likely to
undertake steps to protect its market share against biosimilar
mAb competition (Morisot et al., 2013), and has a better position
to offer a differentiated product. The innovator companies
protect their market share not only by patent strategies but also
through strong ties with physicians and patients.
The innovator companies often have a long lasting
relationship with the physicians, sponsoring clinical research or
offering practical support. Also patient associations often have
strong ties with innovator companies that sponsor their meetings
and offer educational materials.
For many European hospitals, the procurement of
medications is done by a group of hospitals through extensive
negotiation with the pharmaceutical industry (Lepage-Nefkens
et al., 2013). High rebates or interesting research sponsoring
can be given when procurement of medication is concentrated
to a few companies. This can make it difficult for a biosimilar
developer who might not offer as complete a package and
is not able to give the rebate. The extent of the rebates, and
other favorable agreements with hospitals, is often unknown
to the third party payer (Lepage-Nefkens et al., 2013). For
mAbs that are mainly used inside the hospital, it may therefore,
depending on the funding model of the hospital, be profitable
for the hospital to procure the innovator medicine, even if
the biosimilar has a lower list price (and subsequent lower
reimbursement rates). High-cost cancer medication like mAbs,
are often not discounted, because many have no therapeutic
alternative and they are not likely to be continued for outpatient
use (Vogler et al., 2013). This can change when biosimilar mAbs
enter the market offering a lower cost therapeutic alternative.
The innovator company will likely lower the price of the
innovator medicine and therefore biosimilar mAbs cannot rely
on price competition alone but will need to offer a differential
advantage through marketing and service offerings (Bocquet
et al., 2014).
Overcoming the Barriers
Based on the literature review, the following recommendations
are proposed to overcome barriers to the market access of
biosimilar mAbs (Table 3).
Invest Initially in Advanced Production Processes
with the Help of Single-Use Technology, Buy-in of
Experience, or Outsourcing
Technological advances have led to more efficient cell lines that
produce an increased amount of antibody while using more
standardized, less expensive media and thus creating a higher
yield at a lower cost (Calo-Fernández and Martínez-Hurtado,
2012; Gal et al., 2015). The innovator company is bound by the
validated original processes, while the biosimilar developer can
use modern techniques from the start.
TABLE 3 | Recommendations to overcome barriers to market access of
biosimilar monoclonal antibodies in the European Union.
Barrier Recommendation
Manufacturing process • Invest initially in advanced production
processes with the help of single-use
technology, buy-in of experience or outsourcing
Regulatory process • Gain experience with the regulatory process
and establish alignment between stakeholders
Intellectual property rights • Limit patent litigation
• Eliminate evergreening benefits
• Build out further the unitary patent and unified
patent litigation system within the European
Union
Lack of incentive • Create demand-side policies
• Disseminate objective information
Impossibility of substitution • Change attitude toward biosimilar
switching/substitution, starting with physician
and patient education
Innovator’s reach • Differentiate the biosimilar by service offerings
• Use an appropriate comparator in
cost-effectiveness analyses
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The availability of single-use (i.e., disposable) technology in
the development stage of biosimilars may lower the cost involved
in the early development stage (Whitford, 2012).
Further development cost and time savings can be realized
through buy-in of manufacturing experience and outsourcing.
Initial investment in a technically advanced production process
will keep production costs low in the future and lead to a
better competitive position when the biosimilar market becomes
generic like with competition based on price (Rader, 2013).
With the ongoing technological advances in analysis and
manufacturing of biosimilars, this barrier will decrease over time.
Gain Experience with the Regulatory Process and
Establish Alignment between Stakeholders
The EMA guidelines evolved as a compromise between the
different industrial parties, innovator vs. biosimilar, and the
regulatory body. Regulatory authorities need to ensure patient
safety and encourage both competition and innovation in
the biopharmaceutical industry (Blackstone and Fuhr, 2013;
European Medicines Agency, 2016b). The EMA guidelines are
supportive of biosimilar development and it is up to the company
developing the biosimilar to use it to the greatest advantage and
to reduce the need for large and expensive clinical trials.
The historical market approval of biosimilars shows a case-
by-case approach and approval of the marketing authorization
application based on the available test data and the intellectual
judgment of the EMA (Schellekens and Moors, 2010). Profound
knowledge of and experience with the regulatory requirements,
in combination with EMA Scientific advice/Protocol assistance,
will help a company to adjust the biosimilar mAb development
process to these requirements and overcome this barrier for the
EMA regulatory pathway.
Greater alignment between the medical community and the
regulators can lead to greater trust in the regulatory process
(Ebbers et al., 2012a).
Limit Patent Litigation, Eliminate Evergreening
Benefits, Build Out Further the Unitary Patent and
Unified Patent Litigation System within the EU
Innovator companies have protected their mAbs with a myriad of
patents and will likely challenge infringement of these patents by
biosimilar developers. The outcome of these patent disputes will
provide jurisprudence for future cases.
Dylst et al. provide a list of recommendations to enhance
market access of generic medicines (Dylst et al., 2012). Of
these recommendations the following are equally applicable
to biosimilars: (a) Grant patents only for truly innovative
medicines, thereby eliminating evergreening benefits (i.e., follow-
on patents on existing products for non-significant therapeutic
improvements), (b) Create a unitary European Union patent, and
(c) Unified patent litigation within the EuropeanUnion. Plans for
a unitary patent and unified patent litigation are already made
(EPO, 2016). Several EUmember states signed the Agreement on
a Unified Patent Court (EU, 2013).
Create Demand-Side Policies, Disseminate Objective
Information
Positive experience with available biosimilars (Vulto and Crow,
2012) is increasing confidence with payers and physicians and
will positively influence uptake. Not all physicians are familiar
with the concept of biosimilars, neither are they confident
about their safety and efficacy, but awareness has increased over
the years (Noaiseh and Moreland, 2013). Providing objective
information about the characteristics of biosimilars is key in
increasing physician acceptance (Lepage-Nefkens et al., 2013).
Improved communication to physicians, payers, and patients
about the rigor of oversight for biosimilars will improve market
uptake (Schneider et al., 2012). The positive experiences should
strengthen reimbursement authorities, physicians, pharmacists,
and patients to have a positive attitude toward biosimilars and
trust in the EMA biosimilar pathway.
It is argued that a high discount strategy will not overcome
the lack of physician confidence and might easily be countered
by the originator company. The absence of demand-side policies
for biosimilars in many EU member states restricts the potential
price difference between originator and biosimilar (Simoens and
Huys, 2013).
The inclusion of a biosimilar in treatment guidelines, e.g.,
filgrastim biosimilar in European Organization for Research and
Treatment of Cancer (EORTC) guidelines (Aapro et al., 2016)
and infliximab biosimilar in National Institute for Health and
Care Excellence (NICE) guidance (NICE, 2016), will increase
uptake.
The lack of incentive and burden of change barrier will
become less high with the increase of experience and knowledge
of biosimilars and the growing pressure on healthcare budgets.
Change Attitude toward Biosimilar
Switching/Substitution, Starting with Physician, and
Patient Education
Two possible ways are proposed to change the attitude toward
biosimilar switching and substitution. First the realization and
publication of more head-to-head studies with the reference
product, and second strict regulations on biosimilar exchange
quota (Haustein et al., 2012). The Norway Ministry of Health
funded NOR-SWITCH to compare the biosimilar infliximab in
all granted indications with its reference product Remicade R©
after switching from the reference product (Asbjørn, 2015). The
rationale behind setting quota, that the prescription of biosimilar
mAbs to a new patient or the one time switch for an existing
patient may be considered as a low risk, will need to be clearly
communicated, e.g., the position paper of the Finnish medicines
agency (Fimea, 2015). This education is best done through
pharmacists and physicians, who can function as ambassadors.
This communication may cause an increased uptake apart from
the subsequent quota introduction (Lepage-Nefkens et al., 2013).
Information about biosimilars needs to be better spread to all
concerned to raise confidence in the biosimilar development
model. Members of the EMA Biosimilars Working Party have
published two papers with a clear message that biosimilars can
be considered therapeutic alternatives to the reference product
(Weise et al., 2012, 2014).
However, it is unclear in view of the current knowledge
whether back and forth switching may jeopardize patient safety.
For now, it seems that introduction of biosimilars will be largely
limited to new patients, or stable patients where a judiciously
made one-time switch initiated by the prescriber can be made,
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making this barrier most relevant for those biosimilar mAbs with
indications for long-term chronic use like rheumatoid arthritis.
Differentiate the Biosimilar by Service Offerings, Use
an Appropriate Comparator in Cost-Effectiveness
Analyses
Biosimilars may be positioned as late-entrant branded products
rather than generics. The biosimilar developers may need to
develop strategies to differentiate products on the basis of
branding and corporate identity by providing services linked
to the brand identity (Ellery and Hansen, 2012). An optimized
formulation (with e.g., better stability, less painful injections,
more convenient storage conditions) and packaging variants
and sizes are other ways a biosimilar developer can positively
differentiate its biosimilar.
From a health-economic perspective, several aspects need to
be considered. First, with a view to quantifying the value of
second or third generations of biologics using the efficiency
frontier approach (Cleemput et al., 2012), cost-effectiveness
needs to be calculated versus the previous most cost-effective
alternative. This alternative can be a first generation biologic
or the biosimilar. Second, given that pharmaceutical companies
(can) offer discounts/rebates on biologics and biosimilars, prices
of biologics and biosimilars used in a cost-effectiveness analysis
should be prices net of discounts/rebates. Third, economic
pressure can result in lower incremental cost-effectiveness ratio
(ICER) threshold limits (Cleemput et al., 2008). Therefore,
second or third generation biologics will have to prove highly
efficacious or cannot ask a premium price when a biosimilar
or a first generation biologic is used as comparator in the cost-
effectiveness analysis.
However, with the long development time and slow market
uptake, the risk remains that an innovative treatment replaces the
competitive power of a biosimilar mAb before the biosimilar has
become profitable (Declerck, 2013).
Although brandmanufacturers will still defend their reference
products and compete with other biosimilar developers, they
are now producing biosimilars as well. It is thus not in their
interest to campaign indiscriminately against the concept of
biosimilars. An example is how the acquisition of Hospira
by Pfizer led to marketing of biosimilars via their Established
Products Division, which is an independent competitive business
unit. The innovator will still have a competitive advantage
over other biosimilar developers, since biosimilar mAbs that
are developed by innovator companies can benefit from the
company’s network and reputation.
The strong ties that innovator companies have with physicians
through supporting investigator initiated trials can be challenged
when the biosimilar developer has enough credibility, product
and resources to facilitate these trials. This reach of innovator
barrier will become less relevant once biosimilar mAbs are more
accepted as therapeutic alternatives, but will never cease to exist.
CONCLUSION
Our literature search found evidence that market access of
biosimilar mAbs in the EU is hampered by six barriers:
The manufacturing process, the regulatory process, intellectual
property rights, lack of incentive, the impossibility of substitution
and the innovator’s reach. (Table 2)
All of the barriers mentioned above apply more or less to
all biosimilars, which have accordingly seen slow uptake in
European markets (GaBI, 2012; Farfan-Portet et al., 2014).
Based on the literature search the following recommendations
can be done to overcome these barriers to the market access of
biosimilar mAbs (Table 3):
1. Invest initially in advanced production processes with the help
of single-use technology, buy-in of experience or outsourcing.
2. Gain experience with the regulatory process and establish
alignment between stakeholders.
3. Limit patent litigation, eliminate evergreening benefits, build
out further the unitary patent and unified patent litigation
system within the EU.
4. Create demand-side policies, disseminate objective
information.
5. Change attitude toward biosimilar switching/substitution,
starting with physician and patient education.
6. Differentiate the biosimilar by service offerings, use an
appropriate comparator in cost-effectiveness analyses.
In addition to the recommendations above, the authors believe
that within the group of biosimilar mAbs, products of which the
mode of action is better understood, and/or of which the risk of
immunogenicity is thought to be less, the competition is high,
and which are used in short-term treatments, are expected to be
accepted by the market more easily. They are thus expected to
experience faster uptake than products for which the opposite is
valid.
Since biosimilars are approved on a European level, it would
be a good idea to make recommendations on interchangeability
on a European level as well, to support national authorities in
policy development and decision making.
Future research could investigate market dynamics, since
the market is evolving rapidly. Not only the relationship
innovator/biosimilar can be studied, also differences with
second-generation innovator products. Barriers to the market
access of biosimilar mAbs could be reduced when more
transparency and communication/education is used in all steps
toward market access in order to increase the trust in biosimilar
mAbs by all relevant stakeholders. Only then biosimilar mAbs
will be able to fully live up to their cost saving potential.
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